Anthracycline cardiotoxicity: from bench to bedside.

Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB
J Clin Oncol. 2008 26 (22): 3777-84

PMID: 18669466 · PMCID: PMC3018290 · DOI:10.1200/JCO.2007.14.9401

Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerbate the toxicity. The First International Workshop on Anthracycline Cardiotoxicity, held in fall 2006, in Como, Italy, focused on the state-of-the-art knowledge and discussed the research needed to address the cardiotoxicity of these drugs. Here, we incorporate these discussions into the framework of a broader review of preclinical and clinical issues.

MeSH Terms (18)

Animals Anthracyclines Antineoplastic Agents Biomarkers Drug Evaluation, Preclinical Drug Interactions Genetic Predisposition to Disease Heart Heart Diseases Humans Intercellular Signaling Peptides and Proteins Models, Animal Myocardium Oxidative Stress Patient Selection Practice Guidelines as Topic Risk Assessment Risk Factors

Connections (1)

This publication is referenced by other Labnodes entities:

Links